Trials / Active Not Recruiting
Active Not RecruitingNCT06450197
Phase IIa Study Evaluating AZD7798 in Crohn's Disease
A Double-blind, Placebo-controlled Phase IIa Study to Evaluate the Efficacy and Safety of AZD7798 in Patients With Moderate to Severe Crohn's Disease
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomised, double-blind, parallel group, placebo-controlled Phase IIa study designed to evaluate the efficacy and safety of AZD7798 in participants with moderate to severe Crohn's disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD7798 | AZD7798 |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2024-08-28
- Primary completion
- 2026-05-01
- Completion
- 2027-05-14
- First posted
- 2024-06-10
- Last updated
- 2026-04-08
Locations
156 sites across 26 countries: United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, China, France, Germany, Hungary, Italy, Japan, Malaysia, Netherlands, Poland, Romania, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey (Türkiye), Ukraine, Vietnam
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06450197. Inclusion in this directory is not an endorsement.